Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Ingalill Reinholdsson"'
Autor:
Hildur Arnardottir, Sven-Christian Pawelzik, Ulf Öhlund Wistbacka, Gonzalo Artiach, Robin Hofmann, Ingalill Reinholdsson, Frieder Braunschweig, Per Tornvall, Dorota Religa, Magnus Bäck
Publikováno v:
Frontiers in Physiology, Vol 11 (2021)
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). SARS-CoV-2 triggers an immune response with local inflammation in the lung, which may extend to a systemic hyperinflammatory react
Externí odkaz:
https://doaj.org/article/5b3a8175eda043468839ae9202f81f17
Autor:
Hildur, Arnardottir, Sven-Christian, Pawelzik, Ulf, Öhlund Wistbacka, Gonzalo, Artiach, Robin, Hofmann, Ingalill, Reinholdsson, Frieder, Braunschweig, Per, Tornvall, Dorota, Religa, Magnus, Bäck
Publikováno v:
Frontiers in Physiology
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). SARS-CoV-2 triggers an immune response with local inflammation in the lung, which may extend to a systemic hyperinflammatory react
Autor:
Matts Kågedal, Olof Borgå, Dag Nilsson, Yi-Fang Cheng, Ingalill Reinholdsson, Gunilla Huledal, Nils Åsenblad, David Pekar
Publikováno v:
The Journal of Clinical Pharmacology. 47:1043-1048
Autor:
Gunilla Huledal, Olof Borgå, Mischa van Hout, Ingalill Reinholdsson, Matts Kågedal, Hanna Svensson, Dag Nilsson, Yi‑Fang Cheng
Publikováno v:
Current Medical Research and Opinion. 23:1531-1539
NXY-059 is a novel free-radical trapping neuroprotectant. Digoxin treatment is common in acute ischaemic stroke, the intended patient population for NXY-059. Since both digoxin and NXY-059 are eliminated primarily renally, with a substantial contribu
Autor:
Hanna Svensson, Bror Jonzon, Hans Quiding, Christian Åkermark, Märta Segerdahl, Ingalill Reinholdsson
Publikováno v:
PainReferences. 154(11)
A randomized, double-blind, three-period cross-over study was performed to characterize the sensory phenotype and pain demographics in patients with Morton neuroma ( n = 27) and to explore the effects of local administration (2 mL) of placebo and lid
Autor:
Dag Nilsson, Wenyu Guo, Yi-Fang Cheng, Ingalill Reinholdsson, Nils Åsenblad, Pei Hu, Ji Jiang
Publikováno v:
Clinical therapeutics. 30(12)
Background: NXY-059 is a free radical-trapping neuroprotectant that has been reported to reduce infarct size and preserve brain function in experimental models of acute ischemic stroke. NXY-059 administered as an 8- or 72-hour IV infusion has been re
Autor:
Nils Egberg, Dag Nilsson, Johan Wemer, Gunnar Englund, Sam Schulman, Yi-Fang Cheng, Ingalill Reinholdsson
Publikováno v:
Journal of clinical pharmacology. 47(2)
NXY-059 is a novel free radical-trapping neuroprotectant that reduces infarct size and preserves brain function in animal models of acute ischemic stroke. It is the first neuroprotectant to demonstrate a reduction in global disability in a phase III